98 results about "Pancreatic beta Cells" patented technology

Disclosed herein are compositions and methods related to differentiation of stem cells into pancreatic islet cells. In some embodiments, the methods provided herein relate to generation of pancreatic β cell, α cell, δ cells, and EC cells in vitro. In some embodiments, the disclosure provides pharmaceutical compositions including the cells generated according to the methods disclosed herein, as well as methods of treatment making use thereof.

The invention relates to the technical field of biological pharmacy, in particular to application of a recombinant protein DEL-1 in preparation of a medicine for resisting pancreatic beta cell inflammation. The recombinant protein DEL-1 has a remarkable inhibition effect on pancreatic beta cell inflammatory response induced by high glucose and high fat. Experiments show that in an islet beta cell inflammation model constructed by combining high glucose with palmitic acid, DEL-1 can significantly reduce the expression level of inflammatory factors such as IL-1beta, IL-6, TNF-alpha and the like. The DEL-1 is proved to have a definite effect of resisting pancreatic beta cell inflammation.

The invention relates to the technical field of health-care products, in particular to a health-care product rich in momordica charantia polypeptide and capable of regulating blood sugar metabolism and promoting insulin secretion, momordica charantia polypeptide can stimulate pancreatic beta cells to secrete insulin, and insulin is the only hormone capable of reducing blood sugar in a human body. The balsam pear polypeptide component in the balsam pear extract is specially used for reducing the blood sugar level and improving related health problems, the application of the balsam pear polypeptide in the health care product can effectively regulate the blood sugar metabolism of a human body and promote the secretion of insulin, and the balsam pear polypeptide stimulates pancreas islet beta cells to promote the secretion of insulin. In addition, the balsam pear polypeptide can improve the insulin resistance, increase the number of insulin receptors or enhance the activity of the insulin receptors, so that the body cells are more sensitive to the insulin, the uptake and utilization of glucose are promoted, and the abnormal increase of the blood glucose level is avoided.

The invention relates to methods of generating pancreatic beta cells using forward reprogramming.

The present invention relates to a peptide complex having an antidiabetic activity and to a use thereof. The peptide complex of the present invention promotes uptake of glucose into cells, suppresses insulin resistance signals, promotes insulin sensitivity signals, and suppresses the death of pancreatic beta cells, which are insulin-producing cells, thereby exhibiting an effect of lowering blood glucose levels. In addition, the present invention relates to a peptide having an antidiabetic activity and an antiobesity activity and to a use thereof. The peptide of the present invention has an activity of suppressing insulin resistance signals, promoting insulin sensitive signals, and promoting fat decomposition in adipocytes.

The invention discloses a composite combined preparation for synergistically treating and conditioning diabetes, relates to the technical field of foods, health foods or dietary supplements for adjuvant therapy and health care of diabetes, and in particular relates to a composite combined preparation for synergistically treating and conditioning diabetes. The preparation comprises albumin peptide, saussurea involucrata culture, vitamin B1, vitamin B2, wheat oligopeptide, corn oligopeptide, collagen peptide, mulberry leaf extract, rhizoma polygonati extract, sea-buckthorn extract, isomaltitol, maltodextrin, ginseng extract and bitter gourd extract. Through the synergistic effect of all the components, comprehensive auxiliary conditioning on diabetes is realized from multiple targets of maintaining colloid osmotic pressure and nutrition, regulating glycolipid metabolism in multiple ways, protecting pancreatic beta cell functions, enhancing insulin sensitivity, preventing nerve and blood vessel complications, meeting special diet requirements and the like. The composition can be prepared into food, health-care food or dietary supplement and other dosage forms.

Disclosed herein include methods, compositions, and kits suitable for use in cell therapy. In some embodiments, there are provided methods and compositions for differentiating stem cells into pancreatic beta cells capable of producing insulin.

The present disclosure relates to a method of generating pancreatic lineage cells, e.g. islet-like cell aggregates comprising pancreatic beta cells, comprising the steps of providing a single cell suspension of a population of endocrine progenitor cells (EP), allowing the EP cells in the single cell suspension to form 3D structures, and culturing the cells under conditions allowing differentiation into pancreatic mono-hormonal beta cells. The present disclosure also relates to islet-like cell aggregates obtainable by said method and their medical use.

The invention relates to application of lactobacillus acidophilus LA85 in preparation of a product with a blood sugar reducing effect. The brand new application of the lactobacillus acidophilus LA85 strain is developed, namely the lactobacillus acidophilus LA85 strain is used for inhibiting alpha-glucosidase, reducing blood sugar and improving diabetes mellitus, and tests prove that the food intake, the water intake and the urine volume of a mouse with type II diabetes mellitus can be effectively controlled after intervention of the LA85 strain, and the weight value of the mouse is stabilized; the glucose absorption and metabolism capability of diabetic mice is effectively improved, and continuous damage of pancreatic beta cell functions is retarded; the blood lipid level disorder state of the mouse with the type II diabetes mellitus is improved; the inflammation level of a mouse body with type II diabetes mellitus is reduced, and the immunity is improved; and a very good improvement and recovery effect is achieved on abundance and diversity reduction of intestinal flora of the type II diabetes mellitus mice.

The invention belongs to the field of new application of medicines, and particularly relates to application of triptolide in preparation of medicines for treating diabetic vascular obstruction complications. Diabetes vascular obstruction is a common serious complication of diabetes and can cause various tissue injuries such as cardiovascular diseases, nephropathy and retinopathy. Experiments prove that the triptolide can remarkably improve the problems of blood vessel blockage, blood flow slowing, abnormal neovascularization and the like caused in a high-glucose environment, and meanwhile, the expression of blood glucose related indexes (such as Glucose and HbA1c) and inflammatory factors (such as TNF-alpha and IL-1beta) is reduced. In addition, triptolide can also protect pancreas from high glucose damage and improve functions of pancreatic beta cells. According to the invention, the clinical application range of the triptolide is expanded, and a new candidate substance is provided for drug treatment of diabetic vascular complications.

The invention relates to the technical field of medicines, in particular to application of a recombinant protein DEL-1 in preparation of a medicine for resisting pancreatic beta cell senescence. Within the concentration range of 400-1000 ng / ml, the DEL-1 can reduce the high glucose and high fat induced pancreatic beta cell SA-beta-Gal positive rate by 39.5% or above, and the anti-aging effect is remarkable.

The invention provides a high-stress-tolerance pancreas islet organ as well as a preparation method and application thereof. Specifically, the invention provides a method for preparing pancreas islet organs. The invention also provides a use of a reagent combination comprising (a) a pancreatic islet organ and (b) a compound of formula I or a pharmaceutically acceptable salt thereof. In the presence of the compound shown in the formula I or the pharmaceutically acceptable salt thereof, pancreatic endocrine progenitor cells are cultured, so that the increase of the differentiation proportion of pancreatic beta cells is promoted, and pancreatic islet organs with high stress tolerance are obtained; according to the present invention, the combination of the pancreatic islet organ and the compound represented by the formula I or the pharmaceutically acceptable salt thereof can significantly improve and alleviate the integration stress reaction generated during the pancreatic islet organ transplantation compared to the only transplantation treatment, such that the pancreatic islet beta cell identity loss is resisted, and the stress tolerance of the pancreatic islet organ is significantly improved; therefore, the invention provides a new strategy for the treatment of diabetes, and has a wide application prospect.

The invention relates to a preparation method and application of ganoderma lucidum and coix seed mycoplasm, and belongs to the technical field of traditional Chinese medicine and health food processing. According to the preparation method of the lucid ganoderma and coix seed mycoplasm, the lucid ganoderma and coix seed mycoplasm is obtained through liquid fermentation by taking coix seeds as a fermentation substrate and lucid ganoderma as a fermentation strain. The ganoderma lucidum and coix seed mycoplasm composition is obtained through a ganoderma lucidum and coix seed two-way fermentation technology, functional ingredients are increased, and the ganoderma lucidum and coix seed mycoplasm composition has the effects of enhancing immunity, protecting pancreas islet beta cells and improving glycolipid metabolism. The invention develops the application of the traditional Chinese medicine composition in the fields of food and health care products.

The invention relates to a preparation method for inducing and differentiating pancreatic beta cells by using double-gene modified stem cells, relates to the technical field of biology, and provides a double-gene expression pAdxsi-CMV-PDXI / CMV-NeuroD1 adenovirus vector. A three-dimensional culture system for efficiently inducing the hUSCs to be differentiated into the pancreas islet beta cells is constructed by recombining pAdxsi-GFP-PDXI / NeuroD1 adenovirus modified urine-derived stem cell combined cell factors and combining NunclonSphera 3D culture consumables, so that the problems that the pancreas islet beta cell induced differentiation rate is low due to the fact that an optimal three-dimensional cell microenvironment cannot be provided for pancreas islet cell growth and clustering by a traditional two-dimensional culture method; meanwhile, the problems of poor insulin synthesis and secretion functions and the like of a traditional cytokine induction method are solved.

The present application discloses cell clusters resembling the function and characteristics of endogenous pancreatic islets, and methods for making and using such cell clusters. The present disclosure provides an in vitro cell cluster comprising at least one non-native pancreatic β cell that exhibits an in vitro glucose-stimulated insulin secretion response when exposed to a glucose challenge, wherein the cell cluster is an unsorted cell cluster, and wherein the cell cluster comprises: at least 35% of cells that express NKX6.1 and C-peptide; at least 70% of cells that express chromogranin A; at most about 2% of cells that express SOX2; or at most about 10% of cells that express SOX9. In some cases, when transplanted into a subject, the in vitro cell cluster exhibits an in vivo glucose-stimulated insulin secretion response to a glucose challenge in the subject.

The invention belongs to the technical field of natural medicines, and discloses an application method of a synsepalum dulcificum extract in treatment of diabetes mellitus, and the synsepalum dulcificum extract is a natural plant extract and has no obvious toxic or side effect. Compared with chemically synthesized drugs, the traditional Chinese medicine composition does not cause serious damage to important organs such as liver and kidney after long-term use, and the tolerance of patients is good. The hypoglycemic effect is achieved by increasing insulin sensitivity, adjusting activity of glucose metabolism related enzymes, protecting pancreatic beta cells and the like, and the metabolic condition of diabetic patients can be more comprehensively improved. The preparation process of the extract is relatively simple, low in cost and easy for large-scale production. Meanwhile, medicines or health-care products based on the extract have various dosage forms, and can be selected according to the requirements and preferences of patients.

The present application relates to the technical field of mRNA vaccine, and specifically discloses a proinsulin mRNA vaccine for protecting the function and quantity of pancreatic beta cells. The vaccine is composed of a lipid nanoparticle (LNP) and an mRNA wrapped by the LNP; the mRNA is an mRNA sequence encoding proinsulin, and all uridines in the mRNA sequence are replaced by N1-methyl pseudouridine. The mRNA vaccine of the present application realizes the dual protection of the quantity and function of pancreatic beta cells, compared with the existing intervention means which only focus on blood glucose control or immune regulation, the present application delays the occurrence process of type 1 diabetes from the root, and provides a new technical scheme and drug selection for the prevention and early intervention of type 1 diabetes.

The invention discloses a synthesis method of a fullerene nano material with glycolipid metabolism regulation capability, and belongs to the technical field of material science and biomedical engineering. The fullerene and the metformin are combined through chemical bonds, the strong oxidation resistance of the fullerene and the hypoglycemic effect of the metformin are exerted at the same time, the synergistic treatment effect is formed, and the drug composition is superior to a single drug; active oxygen in cells can be efficiently removed, oxidative stress is effectively relieved, and the functions of pancreatic beta cells are protected; through structural modification, the problem of low bioavailability caused by hydrophobicity of fullerene and hydrophilicity of metformin is solved, and the solubility and absorption efficiency of the medicine are improved; in conclusion, through chemical combination of the fullerene and the metformin, a dual-mechanism synergistic effect of oxidation resistance and blood sugar reduction is achieved, the treatment effect is remarkably improved, meanwhile, good safety and biocompatibility are achieved, and important application value is achieved in the field of treatment of the type II diabetes mellitus.

The invention discloses a type 2 diabetes mellitus mouse model construction method combining artificial intelligence prediction and multi-target knockout. Acquiring and standardizing mouse multi-omics data and phenotype baseline data to form a standardized modeling data set; constructing an interaction map covering the functions of the pancreatic beta cells on the basis of the data; screening to obtain a target combination and a target phenotype prediction result, generating a construction instruction, and submitting the construction instruction to a controlled facility to execute multi-gene knockout transformation, so as to obtain a transformed mouse and a transformation receipt; acquiring actual measurement phenotype data of the transformed mouse based on the transformation receipt, and comparing the actual measurement phenotype data with a target phenotype prediction result to generate phenotype deviation measurement and a phenotype judgment result; and when the phenotype determination result is satisfied, registering the target combination, the prediction result, the actually measured phenotype data and the transformation receipt to form the type-2 diabetes mellitus composite mouse model. According to the method, AI-driven multi-target genetic modification closed-loop optimization is realized, and the efficiency and accuracy of complex metabolic disease animal model construction are improved.

Methods and compositions of matter for production of pancreatic beta cells, as well as beta-like cells that are capable of producing insulin. Pluripotent stem cells are generated through either viral vector or non-viral vector means and induced into differentiation pathways through environments resembling the pluripotent pancreatic environment. In vivo transfection of dedifferentiation and beta cell differentiation genes are provided in vivo in the pancreatic microenvironment to generate de novo beta cells and islets from differentiated tissue or islet progenitors. Means of inducing differentiation of islet progenitors in vivo are also provided.

The invention discloses a method for efficiently and directionally inducing IPS to be differentiated into pancreatic beta cells. According to the method, through staged signal regulation and strict cell screening, the directionality and the overall efficiency of differentiation are remarkably improved. The whole process pays attention to cell quality control from the initial stage, and a stable foundation is laid for subsequent differentiation by screening iPS cells with uniform morphology and high expression of pluripotent markers. Progressive signal molecule regulation is adopted in each stage, and an accurate differentiation path is formed from Activin A gradient adjustment during endoderm induction, synergistic effect of FGF10 and retinoic acid in pancreatic precursor cell differentiation and Wnt signal inhibition during endocrine precursor cell induction, so that the non-specific differentiation tendency is effectively reduced. Meanwhile, cell enrichment steps of key nodes, such as SOX17 positive cell screening in an endoderm stage and Ngn3 magnetic bead sorting of endocrine precursor cells, further improve the purity of a target cell population and avoid interference of parenchyma cells on subsequent function maturation.

Provided is a method of differentiating human pluripotent stem cells (hPSCs) into mature pancreatic β cells, comprising contacting hPSC-derived, differentiated immature pancreatic β cells with a histone deacetylase (HDAC) inhibitor.

The invention discloses an immune tolerance realization method based on immune cell negative selection, which comprises the following steps: step 1, separating mononuclear cells from peripheral blood of a patient, and inducing and differentiating the mononuclear cells into DCs in vitro; 2, introducing the Aire gene into DCs by using a virus vector adeno-associated virus (AAV) or a lentivirus; 3, over-expressing Aire protein by the modified DCs, so that the modified DCs can express a plurality of autoantigens; and step 4, injecting the DCs subjected to Aire overexpression back into the body of the patient, and inducing immune tolerance. The preparation method has the beneficial effects that the immune regulation function of DCs is enhanced through the Aire gene, the activity of autoreactive T cells is inhibited, and the damage to pancreatic beta cells is reduced; dependence on a traditional immunosuppressor is reduced, and side effects are reduced; a novel treatment method is provided for autoimmune diseases such as type 1 diabetes, and high safety and specificity are achieved.

Disclosed herein are methods of treating a subject for a condition associated with insufficient insulin secretion by administering to a subject in need of treatment for a condition associated with an insufficient level of insulin secretion a dual-specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1A) inhibitor, a glucagon-like peptide-1 receptor (GLP1R) agonist, and an immunomodulatory monoclonal antibody and / or an immunosuppressive agent (e.g., anti-CD3 antibody), where said administering is carried out under conditions effective to reverse loss of β-cell mass and function in the subject to treat the subject for the condition associate with insufficient insulin secretion. Also disclosed is a composition and a method of increasing β-cell mass and function in a population of pancreatic beta cells.

The invention discloses application of tacrolimus in preparation of a medicine for treating type 2 diabetes and complications thereof, and belongs to the field of biological medicine. Animal experiments prove that Tacrolimus (TM) can effectively improve type 2 diabetes mellitus and obesity-related abnormal glycolipid metabolism. In addition, the TM can also relieve liver injury caused by diabetes and obesity and improve liver fatty degeneration and abnormal lipid metabolism. What's more important is that toxicity of TM to pancreatic beta cells is not observed in long-term multi-model experiments (including diabetes, obesity and elderly mice). The invention provides an important basis for developing novel diabetes treatment drugs, lays a foundation for expanding new indications of tacrolimus, and has potential clinical transformation value.

The invention discloses an application of a jerusalem artichoke tuber alcohol extract in preparation of a medicine for treating type 2 diabetes mellitus, and belongs to the technical field of medicines, the chemical components of the jerusalem artichoke tuber alcohol extract are mainly flavonoid substances, and the jerusalem artichoke tuber alcohol extract can remarkably recover the weight of a mouse with the type 2 diabetes mellitus and improve glucose metabolism indexes such as fasting blood-glucose and oral glucose tolerance; meanwhile, insulin sensitivity is stimulated to secrete insulin, and the functions of pancreatic beta cells are recovered; in addition, the concentration of biochemical indexes such as total cholesterol and triglyceride in the liver is reduced, lipid metabolism of the liver is improved, and a new direction is provided for research and development of natural plant source hypoglycemic products.

The invention relates to a preparation method of ferroptosis regulating nanoparticles based on unsaturated fatty acid, the lipid nanoparticles are prepared by compounding a model drug, monounsaturated fatty acid and phospholipid polyethylene glycol conjugates with different PEG molecular weights, and the method comprises the following steps: mixing the model drug, the monounsaturated fatty acid and the phospholipid polyethylene glycol conjugates with different PEG molecular weights; dissolving in ethanol, ultrasonically mixing uniformly, dropwise adding into deionized water, stirring, performing rotary evaporation, removing methanol and ethanol, centrifuging, removing supernate, and drying to obtain the product. The pharmaceutical composition is rich in raw materials, simple in preparation method, easy to produce, good in product quality and stable in property, polyphenol drugs can be effectively delivered to pancreatitis parts, the bioavailability of the drugs and the pancreatitis targeting capacity are greatly improved, ferroptosis of pancreatic beta cells is inhibited, and the effect of treating diabetes mellitus is achieved. The traditional Chinese medicine composition is a great innovation in medicines for treating diabetes and pancreatitis, and has huge social and economic benefits.

The present invention provides methods to promote the differentiation of pluripotent stem cells. In particular, the present invention provides methods to produce a population of cells, wherein greater than 10% of the cells in the population express markers characteristic of single hormonal pancreatic beta cells.

The present application provides compositions of induced pluripotent stem cells (iPSCs) or pancreatic beta cells and poxviruses, as well as methods of making the compositions and methods of using the compositions to treat diseases.

The invention discloses an application of WBSCR16 protein as a target spot in preparation of a medicine for treating diabetes, and provides an application in research and development of related medicines. By constructing a mouse model of Wbscr16 with pancreatic beta cells specifically knocked out, the action mechanism of WBSCR16 in diabetes mellitus attack is deeply researched, and it is found that WBSCR16 participates in regulating the mitochondrial function of the pancreatic beta cells, and then insulin secretion is affected. On the basis, the invention provides a reagent for regulating the expression of the WBSCR16 protein for treating diabetes mellitus. Meanwhile, a construction method of the Wbscr16 pancreatic beta cell specific knockout mouse model is described in detail, and an important tool is provided for related research. Meanwhile, candidate drugs capable of acting on a WBSCR16 target spot are screened out through drug prediction, and a new strategy and a potential intervention direction are provided for treatment of diabetes mellitus.